

1642 RECEIVED  
APR 26 2000  
PATENT CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT and documents submitted therewith are being deposited with the United States Postal Service as first class mail, postage prepaid thereon, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Thomas E. Northrup  
Thomas E. Northrup, Reg. No. 33,268  
Date 4-20-2000

PT#4

Applicant	:	Sherman	)	Group: 1642
Serial No.	:	09/277,064	)	Examiner: Unassigned
Filed	:	March 26, 1999	)	
For	:	IN VIVO ACTIVATION OF TUMOR-SPECIFIC CYTOTOXIC T CELLS	)	Our Ref. TSRI 433.1 D1



INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In recognition of their continuing duty to disclose pursuant to 37 CFR 1.56, Applicants hereby submit the present Information Disclosure Statement and accompanying PTO Form 1449 in compliance therewith.

Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Information Disclosure Statement may be material pursuant to 37 CFR 1.56, it shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability unless specifically designated as such.

Applicants are filing the present statement pursuant to 37 CFR

Serial No.: 09/277,064

TSRI 433.1 D1

§1.97(b) insofar as this statement is being filed within three months of the filing of the application/before the mailing date of a first Office Action.


Also, in accordance with 37 CFR 1.97 (g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR 1.56 exists.

Respectfully submitted,

Dated: 4-20-2000

By Thomas E. Northrup  
Thomas E. Northrup, Reg. No. 33,268

THE SCRIPPS RESEARCH INSTITUTE  
Office of Patent Counsel  
10550 North Torrey Pines Road  
Mail Drop TPC-8  
La Jolla, CA 92037  
(858) 784-2937

<b>FORM PTO-1449</b> <b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>		<b>ATTY DOCKET NO.</b> TSRI 433.1 D1	<b>SERIAL NO.</b> 09/277,064
		<b>APPLICANT</b> Sherman	
		<b>FILING DATE</b> 3/ 26/ 1999	<b>GROUP</b> 1642

## U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE


## FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

✓	19	Guo, et al., "Different Length Peptides Bind to HLA-Aw68 Similarly at Their Ends But Bulge Out in the Middle", <u>Nature</u> 360: 364-366 (1992)
✓	20	Boon, "Tumor Antigens Recognized by Cytolytic T Lymphocytes: Present Perspectives for Specific Immunotherapy", <u>Int. J. Cancer</u> 54: 177-180 (1993)
✓	21	Melief, et al., "Potential Immunogenicity of Oncogene and Tumor Suppressor Gene Products", <u>Curr. Opin. Immunol.</u> 5: 709-713 (1993)
✓	22	Houbiers, et al., " <i>In Vitro</i> Induction of Human Cytotoxic T Lymphocyte Responses Against Peptides of Mutant and Wild-Type p53", <u>Eur. J. Immunol.</u> 23: 2072-2077 (1993)
✓	23	Ruppert, et al., "Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules", <u>Cell</u> 74: 929-937 (1993)
✓	24	Nijman, et al., "p53, a Potential Target for Tumor-Directed T Cells", <u>Immunol. Lett.</u> 40: 171-178 (1994)
✓	25	Pietras, et al., "Antibody to HER-2/ <i>neu</i> Receptor Blocks DNA Repair After Cisplatin in Human Breast and Ovarian Cancer Cells", <u>Oncogene</u> 9: 1829-1838 (1994)
✓	26	Tilkin, et al., "Primary Proliferative T Cell Response to Wild-Type p53 Protein in Patients with Breast Cancer", <u>Eur. J. Immunol.</u> 25: 1765-1769 (1995)
✓	27	Nijman, et al., "Characterization of Cytotoxic T Lymphocyte Epitopes of a Self-Protein, p53, and a Non-Self-Protein, Influenza Matrix: Relationship Between Major Histocompatibility Complex Peptide Binding Affinity and Immune Responsiveness to Peptides", <u>J. Immunotherapy</u> 14: 121-126 (1993)
•	28	Spitler, "Cancer Vaccines: The Interferon Analogy", <u>Cancer Biotherapy</u> 10: 1-3 (1995)
•	29	Ezzell, "Cancer "Vaccines": An Idea Whose Time Has Come?", <u>J. NIH Res.</u> 7: 46-49 (1995)
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>FORM PTO-1449</b> <b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>		<b>ATTY DOCKET NO.</b> TSRI 433.1 D1	<b>SERIAL NO.</b> 09/277,064
		<b>APPLICANT</b> Sherman	
		<b>FILING DATE</b> 3/26/1999	<b>GROUP</b> 1642

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**
**U.S. PATENT DOCUMENTS**

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	1	5,112,948	5/12/1992	C. Michael Jones			
	2	5,292,642	3/8/1994	C. Michael Jones			
	3	5,434,247	7/18/1995	C. Michael Jones			
	4	5,679,641	10/21/1997	Melief, et al.			

**FOREIGN PATENT DOCUMENTS**

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	5	WO 93 24525	12/9/1993	PCT			
	6	WO 94 20127	2/17/1994	PCT			
	7	WO 94 20127	9/15/1994	PCT			

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)**

✓	8	Allen, et al., "Identification of the T-Cell and Ia contact residues of a T-cell Antigenic Epitope", <u>Nature</u> 327: 713-715 (1987)
✓	9	Sette, et al., "Structural Characteristics of an Antigen Required for its Interaction with Ia and Recognition by T cells", <u>Nature</u> 328: 395-399 (1987)
✓	10	Deres, et al., "In Vivo Priming of Virus-Specific Cytotoxic T lymphocytes with Synthetic Lipopeptide Vaccine", <u>Nature</u> 342: 561-564 (1989)
✓	11	Vitiello, et al., "Analysis of the HLA-Restricted Influenza-Specific Cytotoxic T Lymphocyte Response in Transgenic Mice Carrying a Chimeric Human-Mouse Class I Major Histocompatibility Complex", <u>J. Exp. Med.</u> 173: 1007-1015 (1991)
✓	12	Jardetzky, et al., "Identification of Self Peptides Bound to Purified HLA-B27", <u>Nature</u> 353: 326-329 (1991)
✓	13	Farouqi, et al., "Establishment of T-Lymphoid Cell Lines from Moroccan Patients with Tropical Spastic Paraparesis", <u>AIDS RESEARCH AND HUMAN RETROVIRUSES</u> 8: 1209-1213 (1992)
✓	14	van der Bruggen, et al., "Molecular Definition of Tumor Antigens Recognized by T Lymphocytes", <u>Curr. Opin. Immunol.</u> 4: 608-612 (1992)
✓	15	Lane, "p53, Guardian of the Genome", <u>Nature</u> 358: 15-16 (1992)
✓	16	Ullrich, et al., "The p53 Tumor Suppressor Protein, a Modulator of Cell Proliferation", <u>J. Biol. Chem.</u> 267: 15259-15262 (1992)
✓	17	Hartwell, "Defects in a Cell Cycle Checkpoint May be Responsible for the Genomic Instability of Cancer Cells", <u>Cell</u> 71: 543-546 (1992)
✓	18	Epstein, et al., "Synthetic Phosphopeptide Immunogens Yield Activation-Specific Antibodies to the c-erbB-2 Receptor", <u>Proc. Natl. Acad. Sci. USA</u> 89: 10435-10439 (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.